Sfoglia per Autore
Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection
2010 R. Ben-Ami;R. E. Lewis;D. P. Kontoyiannis
Toll-deficient Drosophila are resistant to infection by Pneumocystis spp. Additional evidence of specificity to mammalian hosts
2010 S. E. Evans;K. Leventakos;R. Ben-Ami;D. You;S. G. Thakkar;R. E. Lewis;D. P. Kontoyiannis
Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis
2010 M. A. Milito;D. P. Kontoyiannis;R. E. Lewis;P. Liu;O. R. Mawlaw;M. T. Truong;E. M. Marom
Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus
2011 R. E. Lewis;G. Liao;J. Hou;R. A. Prince;D. P. Kontoyiannis
Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection
2011 R. E. Lewis;G. Liao;W. Wang;R. A. Prince;D. P. Kontoyiannis
Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species
2011 S. C. .;R. E. Lewis;D. P. Kontoyiannis
Efficacy of Caspofungin in Neutropenic and Corticosteroid-Immunosuppressed Murine Models of Invasive Pulmonary Mucormycosis
2011 R. E. Lewis;K. Leventakos;G. Liao;D. P. Kontoyiannis
Current Concepts in Antifungal Pharmacology
2011 R. E. Lewis
Pharmacokinetic-pharmacodynamic optimization of triazole antifungal therapy
2011 R. E. Lewis
How I treat mucormycosis
2011 D. P. Kontoyiannis;R. E. Lewis
Activity of Deferasirox in Mucorales: Influences of Species and Exogenous Iron
2011 R. E. Lewis;G. N. Pongas;N. Albert;R. Ben-Ami;T. J. Walsh;D. P. Kontoyiannis
Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia Species
2011 M. Z. R.;R. E. Lewis;D. P. Kontoyiannis
Fungal Drug Resistance and Pharmacologic Considerations of Dosing Newer Antifungal Therapies
2011 Lewis; Perlin David S.
In vitro interactions among echinocandins against Aspergillus fumigatus: lack of concordance among methods
2011 R. Ben-Ami;R. E. Lewis;D. P. Kontoyiannis
Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance
2011 R. Ben-Ami;G. Garcia-Effron;R. E. Lewis;S. Gamarra;K. Leventakos;D. S. Perlin;D. P. Kontoyiannis
Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma
2012 J. M. Julius;A. Gaikwad;A. Lowry;R. E. Lewis;R. D. Lozano;J. L. Dalrymple;R. L. Coleman;J. A. Smith
Importance of Pharmacokinetic Considerations for Selecting Therapy in the Treatment of Invasive Fungal Infections
2012 R. E. Lewis
How Does Antifungal Pharmacology Differ for Mucormycosis Versus Aspergillosis?
2012 R. E. Lewis;O. Lortholary;B. Spellberg;E. Roilides;D. P. Kontoyiannis;T. J. Walsh
Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches
2012 N. D. Beyda;R. E. Lewis;K. W. Garey
Future Directions in Mucormycosis Research
2012 D. P. Kontoyiannis;R. E. Lewis;O. Lotholary;B. Spellberg;G. Petrikkos;E. Roillides;A. Ibrahim;T. J. Walsh
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile